{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Katherine Bibeau came here in March, to a red-brick doctor's office tucked between a furniture store and a steel factory, looking to slow her physical decline from multiple sclerosis. Ms. Bibeau, a 53-year-old laboratory technician from Minnesota, met Dr. James Shortt, who practices alternative medicine. He is, according to a sign on the front of the building, a ''longevity physician.''", "headline": {"main": "Death Puts Spotlight on a Doctor and Regulators"}, "abstract": null, "print_page": "16", "word_count": 999, "_id": "4fd2a4848eb7c8105d88ab8a", "snippet": "A South Carolina case has focused attention not just on the danger of an unorthodox therapy but also on the conduct of the state medical board.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/06/national/06doctor.html", "multimedia": [{"url": "images/2004/10/06/national/06doct75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/10/06/national/06doct75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "glocations", "value": "SOUTH CAROLINA"}, {"name": "subject", "value": "ALTERNATIVE MEDICINE"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Adam", "rank": 1, "lastname": "LIPTAK"}], "original": "By ADAM LIPTAK"}, "document_type": "article", "pub_date": "2004-10-06T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Now that Merck has removed its arthritis painkiller Vioxx from the market after tests found that it increased the risk of heart attacks and strokes, its rival Pfizer is taking a surprising stance. Pfizer says it is looking into whether its somewhat similar drug, Celebrex, may actually help prevent heart attacks. ''We're not running away from cardiology,'' Dr. Mitch Gandelman, a Pfizer vice president, said in an interview on Friday, adding that a couple of studies on a very small scale by university scientists suggested that Celebrex could be good for cardiovascular health. ''We are actually looking into cardiology.''", "headline": {"main": "New Scrutiny of Drugs in Vioxx's Family"}, "abstract": "Removal of Merck's arthritis painkiller Vioxx from market because of studies showing it increased risk of heart attacks and strokes leads to more scrutiny of other drugs in widely prescribed group known as COX-2 inhibitors; Pfizer, in surprising stance, says it its looking into whether its somewhat similar drug, Celebrex, may actually help prevent heart attacks; admits evidence so far is scant and inconclusive; safety concerns could delay approval of two other drugs in advanced stages of development, Merck's Arcoxia and Novartis's Prexige, and others further behind; many experts say Celebrex is somewhat different chemically from Vioxx and has not shown signs of increasing cardiovascular risk; graphs of COX-2 inhibitors on market and in pipeline; photo (M)", "print_page": "1", "word_count": 1690, "_id": "4fd23e578eb7c8105d7d4da3", "snippet": "Now that Merck has removed Vioxx from the market, drugs in the same class - both available and awaiting approval - are undergoing renewed scrutiny.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/04/business/04vioxx.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "NOVARTIS AG"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "organizations", "value": "MERCK GROUP"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "COX-2 INHIBITORS (DRUGS)"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "PREXIGE (DRUG)"}, {"name": "subject", "value": "ARCOXIA (DRUG)"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK; Nat Ives contributed reporting for this article"}, "document_type": "article", "pub_date": "2004-10-04T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Style Desk", "lead_paragraph": "HE is a Beverly Hills doctor known for pioneering work in cosmetic dermatology and for a star-studded patient list, where ''Michael'' is for Jackson and ''Elizabeth'' is for Taylor. She is an A-list Hollywood wife, active in the right philanthropies and Democratic Party politics, and married to a famous movie producer. But after a doctor-patient relationship of more than 20 years, Arnold W. Klein and Irena Medavoy are facing off in a medical malpractice trial in Los Angeles Superior Court that has tongues wagging as much about the players as about what they are fighting over: Botox.", "headline": {"main": "Botox Lawsuit Is Raising Eyebrows"}, "abstract": "Article on medical malpractice trial over Botox involving Beverly Hills cosmetic dermatologist Arnold Klein and Irena Medavoy; Medavoy, wife of Phoenix Pictures chairman Mike Medavoy, has accused Klein of treating her with an excessive dose of Botox that caused severe headaches without warning her of risks or disclosing that he was paid consultant for drug maker, Allergan Inc; photos (M)", "print_page": "2", "word_count": 1288, "_id": "4fd23f178eb7c8105d7d5d12", "snippet": "A doctor and his patient are facing off in a medical malpractice trial that has tongues wagging as much about the players as about what they are fighting over: Botox.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/03/fashion/03BOTO.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "MEDAVOY, IRENA"}, {"name": "persons", "value": "KLEIN, ARNOLD W"}, {"name": "glocations", "value": "LOS ANGELES (CALIF)"}, {"name": "organizations", "value": "ALLERGAN INC"}, {"name": "subject", "value": "HEADACHES"}, {"name": "subject", "value": "BOTOX (DRUG)"}, {"name": "subject", "value": "MALPRACTICE"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "SKIN"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Mireya", "rank": 1, "lastname": "NAVARRO"}], "original": "By MIREYA NAVARRO"}, "document_type": "article", "pub_date": "2004-10-03T00:00:00Z", "section_name": "Health; Style"}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "After three years of denying that the arthritis drug Vioxx could induce heart attacks and strokes, this week Merck bowed to reality: it withdrew Vioxx from the market. The impact of this decision is far-reaching, and not only because tens of millions of people have tried Vioxx. It also highlights the absence of Food and Drug Administration oversight of the pharmaceutical industry as well as the lack of comprehensive long-term studies of not only Vioxx but its entire class of arthritis drugs.", "headline": {"main": "Good Riddance to a Bad Drug", "kicker": "Op-Ed Contributor"}, "abstract": "Op-Ed article by Eric J Topol, chairman of cardiovascular medicine at Cleveland Clinic, applauds Merck's withdrawal of Vioxx from market, but says case highlights inadequate Food and Drug Administration oversight of pharmaceutical industry; contends stronger regulatory agency is needed to compel drug companies to do proper studies and prevent direct-to-consumer marketing of drugs that carry risk of heart attack or stroke", "print_page": "15", "word_count": 745, "_id": "4fd247f38eb7c8105d7e3ef8", "snippet": "Merck's withdrawal of the arthritis drug Vioxx highlights the lack of oversight in the pharmaceutical industry.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/02/opinion/02topol.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "CLEVELAND CLINIC"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "ADVERTISING AND MARKETING"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"firstname": "Eric", "middlename": "J.", "lastname": "Topol", "rank": 1, "role": "reported", "organization": ""}], "original": "By Eric J. Topol"}, "document_type": "article", "pub_date": "2004-10-02T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "For years, evidence mounted that the pain reliever Vioxx might increase the risk of heart attacks or strokes. For years, its maker, Merck, disputed such findings. A week ago Thursday, Merck's defense started crumbling, with the arrival of irrefutable evidence from one of the company's own studies that Vioxx doubled a long-term patient's chance of having such problems. And yesterday, after a frantic week of internal huddles and meetings with regulators, Merck announced that it would withdraw the drug from the worldwide market.", "headline": {"main": "For Merck, Defense of a Drug Crumbles at a Difficult Time", "kicker": "MERCK AND VIOXX: THE CLINICAL TESTS"}, "abstract": "Evidence that arthritis drug Vioxx might increase risk of heart attacks or stroke has been mounting since drug was approved for sale in 1999, but Merck & Co, its maker, always disputed such findings; Merck's defense crumbled only after arrival of irrefutable evidence from company's own studies that Vioxx doubled long-term patient's chance of having such problem; short but highly profitable history of Vioxx may prove to be story about triumph of marketing over science; sales of Vioxx soared to $2.5 billion in 2003 on strength of one of biggest direct-to-consumer marketing campaigns yet for prescription medication; in first six months of this year alone, Merck spent estimated $45 million advertising drug (M)", "print_page": "1", "word_count": 847, "_id": "4fd259ac8eb7c8105d806033", "snippet": "For years, evidence mounted that Vioxx might increase the risk of heart attacks or strokes. For years, its maker disputed such findings.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/01/business/01trials.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "MERCK & CO"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "ADVERTISING AND MARKETING"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Barry", "rank": 1, "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2004-10-01T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The drug company Merck announced yesterday that it would stop selling its arthritis and pain medication Vioxx, currently taken by close to two million people worldwide, because a new study found that it doubled patients' risk of heart attack and strokes. Vioxx has been a blockbuster for Merck, with sales of $2.5 billion last year, and has been widely marketed as a safe alternative to drugs like aspirin, which can cause ulcers and gastrointestinal bleeding.", "headline": {"main": "A Widely Used Arthritis Drug Is Withdrawn", "kicker": "MERCK AND VIOXX: THE OVERVIEW"}, "abstract": "Merck drug company says it will stop selling its widely popular arthritis pain medication Vioxx because new study found it doubled patients' risk of heart attack and strokes; this is largest drug recall in history as measured by sales, which were $2.5 billion last year; new study was examining whether Vioxx prevented colon polyps, but Merck quickly ended trial after results of study showed that drug led to heart attacks and strokes; risk is small--15 cases of heart attack, stroke or blood clots per thousand patients over three years compared with 7.5 such events per thousand taking placebo; Merck tells federal regulators it halted trial because data was so unambiguous; previous studies linking Vioxx with heart attacks and strokes were not definitive; Vioxx represents 11 percent of Merck's revenue last year; its stock plunges 27 percent on news; photo; chart (L)", "print_page": "1", "word_count": 1633, "_id": "4fd2801b8eb7c8105d84ad40", "snippet": "Merck said that it would stop selling Vioxx because a study found that it doubled patients' risk of heart attack and strokes.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/01/business/01drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2004-10-01T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Doctors said yesterday that most people who take the painkiller Vioxx should not be overly concerned about its withdrawal from the market because the drug's risks are small and alternatives are available, both by prescription and over the counter. ''The first thing I would say is don't panic,'' said Dr. Hayes Wilson, chief of rheumatology at Piedmont Hospital in Atlanta and a medical adviser to the Arthritis Foundation, an advocacy group.", "headline": {"main": "Doctors Tell Vioxx Users That Alternatives Are Available", "kicker": "MERCK AND VIOXX: THE PATIENTS"}, "abstract": "Doctors say that most people who take painkiller Vioxx should not be overly concerned about its withdrawal from market because drug's risks are small and alternatives are available, both by prescription and over-the-counter (M)", "print_page": "4", "word_count": 705, "_id": "4fd249788eb7c8105d7e6771", "snippet": "Doctors said yesterday that most people who take the painkiller Vioxx should not be overly concerned about its withdrawal from the market because the drug's risks are small and alternatives are available, both by prescription and over the counter.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/01/business/01patient.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "MERCK & CO"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-10-01T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 7, "offset": 0, "time": 94}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}